Microbot Medical Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2023. Although the request references 2023 Q4, this filing reports full-year results and does not provide a clear standalone fourth-quarter financial summary. Amounts below are U.S. dollars; financial statement amounts are generally in thousands unless stated otherwise.
Business context
Microbot is a preclinical medical-device company developing robotic endoluminal surgery technology. Its primary focus is the LIBERTY Endovascular Robotic Surgical System, a proposed disposable, remotely operated system for endovascular procedures. The company has no product revenue and has not obtained marketing clearance or approval.
In 2023, Microbot narrowed its development focus to LIBERTY, discontinued work on its SCS and TipCat platforms, and ended its CardioSert program. It acquired Nitiloop assets, including NovaCross technology, in 2022; the company says NovaCross may support its One & Done feature.
Financial performance and liquidity
| Metric | 2023 | 2022 | Change or context |
|---|---|---|---|
| Revenue | None | None | No revenue from operations in either year. |
| Research and development expense, net | $5.724 million | $7.736 million | Down $2.012 million, principally reflecting cost reductions and reduced or discontinued work on other programs. |
| General and administrative expense, net | $4.131 million | $5.545 million | Down $1.414 million, reflecting cost reductions, lower insurance premiums and share-based compensation, and insurance recoveries. |
| Operating loss | $9.855 million | $13.281 million | Improved as operating expenses declined. |
| Net loss | $10.740 million | $13.168 million | Improved $2.428 million; 2023 included a $1.111 million net legal-settlement loss. |
| Net loss per share, basic and diluted | $1.05 | $1.81 | Weighted-average shares were 10.200 million and 7.260 million, respectively. |
| Cash used in operating activities | $8.533 million | $11.549 million | Lower primarily due to reduced spending. |
| Cash provided by (used in) investing activities | $1.973 million | $(3.836) million | 2023 reflected net proceeds from maturities and sales of marketable securities; 2022 included net purchases. |
| Cash provided by financing activities | $6.558 million | $4.324 million | Higher equity and warrant issuance proceeds in 2023. |
| Cash, cash equivalents and marketable securities at year-end | $6.385 million | $8.202 million | Down $1.817 million. |
| Net working capital | Approximately $4.1 million | Approximately $6.7 million | Declined year over year. |
Balance sheet: Total assets were $8.327 million, total liabilities $3.826 million, and shareholders’ equity $4.501 million at December 31, 2023. Current liabilities included a $2.211 million legal-settlement accrual. The filing reports lease liabilities but no material borrowings or other debt balance in the presented balance sheet. Profit margins are not meaningful because the company had no revenue.
The independent auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about the company’s ability to continue as a going concern. Management estimated available funds would support operations for less than one year from the filing date.
Material developments and outlook
- Development progress: The company reported 100% technical success and usability in a 48-target pivotal preclinical study, with no visually observed acute complications. Earlier 2023 preclinical studies also reported successful target access. These are preclinical results, not evidence of human clinical safety or effectiveness.
- Regulatory: Microbot submitted an IDE application to the FDA on January 29, 2024 to begin a pivotal human clinical trial. As of the filing date, FDA interactions on the submission were continuing; the filing does not establish that the IDE was approved or that a trial had begun. The company also planned ISO 13485 audits in the first half of 2024 as part of its future European CE Mark process.
- Capital raised: May and June 2023 equity and warrant transactions generated approximately $7.6 million gross proceeds, before fees and expenses. In January 2024, holders exercised existing investment options at a reduced $1.62 per-share price; Microbot reported approximately $2.73 million in gross proceeds before fees and expenses and issued new options exercisable at $1.50. These transactions increased or may increase dilution.
- Settlement: A lawsuit related to a 2017 financing was settled in January 2024 for $2.154 million in total consideration: a $1.1 million cash payment covered by insurance and 1,005,965 restricted common shares. The company accrued a $2.211 million liability and recorded a $1.335 million insurance recovery receivable at year-end; the net loss recognized was $1.111 million. The litigation was later discontinued with prejudice.
- Management outlook: No revenue or earnings guidance is provided. The company expects continuing losses and needs additional financing to advance LIBERTY. Management states that failure to raise capital, or unfavorable verification and human-trial results, could require further cost reductions or a shutdown. Salaries and director fees previously reduced or suspended were reinstated by early 2024.
- Key risks: The business depends chiefly on LIBERTY’s development and regulatory path, and the FDA may require additional testing, time and expense. The company relies on third-party manufacturers and suppliers. Israel-based operations face risks from the ongoing military conflict, including supplier and shipping disruption; management reported no material adverse operational effect as of the filing date but had no specific contingency plan for escalation. Other risks include dilution, Nasdaq listing compliance, reimbursement uncertainty, competition, and intellectual-property rights.
- Other unusual items: The company expects to return CardioSert technology after CardioSert exercised its contractual reacquisition right; transfer was expected in the second quarter of 2024. The Stryker collaboration was not moving forward. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an attestation on internal controls.
Most important facts for investors to verify
- Current cash and marketable securities, actual operating runway, and whether subsequent financing has been secured on acceptable terms.
- FDA disposition of the IDE application, trial design and timing, and any additional clinical evidence or costs required by regulators.
- Human-trial results and whether LIBERTY can demonstrate safety, effectiveness, usability and commercial manufacturability.
- Fully diluted share count and the potential impact of outstanding warrants, options, inducement options and restricted settlement shares.
- Progress on ISO 13485 certification and the CE Mark process, plus the effect of Israel-related supplier, workforce and logistics disruptions.
- Completion and accounting consequences of the CardioSert technology return, and the status of the separate $485,000 Mona judgment collection effort.